doi: 10.1016/j.jpeds.2008.07.004.
Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients
Affiliations
- PMID: 19187736
- DOI: 10.1016/j.jpeds.2008.07.004
Item in Clipboard
Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients
J Pediatr.
2009 Jan.
Abstract
We describe the use of enzyme replacement therapy in conjunction with hematopoietic stem cell transplantation in 18 consecutive patients with severe mucopolysaccharidosis type I. The survival and engraftment rate was 89% overall and 93% for the 15 patients who received full-intensity conditioning.
Similar articles
-
Combined enzyme replacement and haematopoietic stem cell transplantation in Hurler syndrome.J Paediatr Child Health. 2009 Jul-Aug;45(7-8):469-72. doi: 10.1111/j.1440-1754.2009.01537.x. J Paediatr Child Health. 2009. PMID: 19712183
-
Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome.Bone Marrow Transplant. 2008 Mar;41(6):531-5. doi: 10.1038/sj.bmt.1705934. Epub 2007 Nov 26. Bone Marrow Transplant. 2008. PMID: 18037941 Clinical Trial.
-
Developmental outcomes in children with Hurler syndrome after stem cell transplantation.Dev Med Child Neurol. 2007 Sep;49(9):646. doi: 10.1111/j.1469-8749.2007.00646.x. Dev Med Child Neurol. 2007. PMID: 17718818 No abstract available.
-
Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation.Pediatr Transplant. 1998 Nov;2(4):250-3. Pediatr Transplant. 1998. PMID: 10084724 Review. No abstract available.
-
Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review.Am J Clin Oncol. 2009 Dec;32(6):618-28. doi: 10.1097/COC.0b013e31817f9de1. Am J Clin Oncol. 2009. PMID: 19593085 Review.
Cited by
-
Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.Curr Pharm Biotechnol. 2011 Jun;12(6):867-83. doi: 10.2174/138920111795542633. Curr Pharm Biotechnol. 2011. PMID: 21235444 Free PMC article. Review.
-
Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I.Cochrane Database Syst Rev. 2019 Jun 18;6(6):CD009354. doi: 10.1002/14651858.CD009354.pub5. Cochrane Database Syst Rev. 2019. PMID: 31211405 Free PMC article.
-
Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I.Mol Ther Methods Clin Dev. 2019 Mar 2;13:321-333. doi: 10.1016/j.omtm.2019.02.007. eCollection 2019 Jun 14. Mol Ther Methods Clin Dev. 2019. PMID: 30976609 Free PMC article.
-
Hematopoietic stem cell gene therapy of neurometabolic lysosomal storage diseases.Brain Dev. 2025 Aug;47(4):104384. doi: 10.1016/j.braindev.2025.104384. Epub 2025 Jun 25. Brain Dev. 2025. PMID: 40570504 Free PMC article. Review.
-
Current and emerging management options for patients with Morquio A syndrome.Ther Clin Risk Manag. 2013;9:45-53. doi: 10.2147/TCRM.S24771. Epub 2013 Feb 11. Ther Clin Risk Manag. 2013. PMID: 23413237 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
